Evidence map›Paper›PMID 40234699›Full record

ArticleScientific reports2025

MiR- 150 deletion promotes lung tumor growth by upregulating P-STAT3 and ROS in MDSCs.

Anqi Qin, Hao Chen, Fan Xu, Wenting Li, Shuai Guo, Ge Zhang, Aihong Zhang, Aihua Zheng, Feng Tian, Quanhui Zheng

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anqi QinHebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research On Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, People's Republic of China.
Hao ChenHebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research On Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, People's Republic of China.
Fan XuHebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research On Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, People's Republic of China.
Wenting LiDepartment of Laboratory Animal Science, Health Science Center, Peking University, Beijing, 100083, People's Republic of China.
Shuai GuoHebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research On Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, People's Republic of China.
Ge ZhangHebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research On Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, People's Republic of China.
Aihong ZhangDepartment of ICU, The Affiliated Hospital of North China University of Science and Technology, Tangshan, 063000, People's Republic of China.
Aihua ZhengEmergency department, Worker's Hospital of Tangshan, Tangshan, 063000, People's Republic of China.
Feng TianDepartment of Laboratory Animal Science, Health Science Center, Peking University, Beijing, 100083, People's Republic of China.
Quanhui ZhengHebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research On Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, People's Republic of China. 1078209929@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the second most common cancer in the world. Myeloid-derived suppressor cells (MDSCs) are important cell populations in the microenvironment of lung cancer, which affects the development and treatment of lung cancer. A large number of studies have shown that miRNA can regulate MDSCs, promoting tumor development. Here we aim to explore the role of miR- 150 on MDSCs in lung tumors. We established lung tumor models by injecting miR- 150 knock-out (miR- 150 KO) mice with LLC subcutaneously. MiR- 150 deletion promoted tumor growth and increased the ratio of MDSCs in tumors. In addition, knockdown of miR- 150 resulted in high serum levels of IL- 6 and G-CSF and promoted the expression of suppressive-associated molecules in MDSCs. In vitro, inhibition of miR- 150 led to increased expression of ROS, IRE1α and P-STAT3 in MDSCs. In vivo administration of STAT3 inhibitor significantly inhibited tumor growth in miR- 150 KO mice and reduced ROS level in tumor MDSCs. Our results indicated that miR- 150 deletion promotes lung tumor growth by upregulating P-STAT3 and ROS in MDSCs, suggesting that STAT3 inhibitors are effective in blocking the production of ROS in MDSCs lacking miR- 150.

Indexed as

Lung NeoplasmsMicroRNAsMyeloid-Derived Suppressor CellsReactive Oxygen SpeciesSTAT3 Transcription FactorAnimalsCell Line, TumorCell ProliferationGene DeletionGene Expression Regulation, NeoplasticMiceMice, Inbred C57BLMice, KnockoutUp-RegulationMicroRNAsReactive Oxygen SpeciesStat3 protein, mouseSTAT3 Transcription FactorIRE1αMDSCMiR- 150ROSSTAT3

Identifiers

PMID40234699
PMCPMC12000323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.